Literature DB >> 29274463

How to: Surveillance of Clostridium difficile infections.

M Krutova1, P Kinross2, F Barbut3, A Hajdu4, M H Wilcox5, E J Kuijper6.   

Abstract

BACKGROUND: The increasing incidence of Clostridium difficile infections (CDI) in healthcare settings in Europe since 2003 has affected both patients and healthcare systems. The implementation of effective CDI surveillance is key to enable monitoring of the occurrence and spread of C. difficile in healthcare and the timely detection of outbreaks. AIMS: The aim of this review is to provide a summary of key components of effective CDI surveillance and to provide some practical recommendations. We also summarize the recent and current national CDI surveillance activities, to illustrate strengths and weaknesses of CDI surveillance in Europe. SOURCES: For the definition of key components of CDI surveillance, we consulted the current European Society of Clinical Microbiology and Infectious Diseases (ESCMID) CDI-related guidance documents and the European Centre for Disease Prevention and Control (ECDC) protocol for CDI surveillance in acute care hospitals. To summarize the recent and current national CDI surveillance activities, we discussed international multicentre CDI surveillance studies performed in 2005-13. In 2017, we also performed a new survey of existing CDI surveillance systems in 33 European countries. CONTENT: Key components for CDI surveillance are appropriate case definitions of CDI, standardized CDI diagnostics, agreement on CDI case origin definition, and the presentation of CDI rates with well-defined numerators and denominators. Incorporation of microbiological data is required to provide information on prevailing PCR ribotypes and antimicrobial susceptibility to first-line CDI treatment drugs. In 2017, 20 European countries had a national CDI surveillance system and 21 countries participated in ECDC-coordinated CDI surveillance. Since 2014, the number of centres with capacity for C. difficile typing has increased to 35 reference or central laboratories in 26 European countries. IMPLICATIONS: Incidence rates of CDI, obtained from a standardized CDI surveillance system, can be used as an important quality indicator of healthcare at hospital as well as country level.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Clostridium difficile infection; Clostridium difficile infection epidemiology; Clostridium difficile typing; Healthcare-associated infection

Mesh:

Year:  2017        PMID: 29274463     DOI: 10.1016/j.cmi.2017.12.008

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  18 in total

1.  Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for Clostridioides (prev. Clostridium) difficile diagnosis in a university hospital in Minas Gerais, Brazil.

Authors:  Carolina Pantuzza Ramos; Emily Oliveira Lopes; Amanda Nádia Diniz; Francisco Carlos Faria Lobato; Eduardo Garcia Vilela; Rodrigo Otávio Silveira Silva
Journal:  Braz J Microbiol       Date:  2020-05-04       Impact factor: 2.476

Review 2.  Treatment of Clostridioides (Clostridium) difficile infection.

Authors:  Jarmo Oksi; Veli-Jukka Anttila; Eero Mattila
Journal:  Ann Med       Date:  2019-12-13       Impact factor: 4.709

Review 3.  Antimicrobial resistance in Clostridioides difficile.

Authors:  Keeley O'Grady; Daniel R Knight; Thomas V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-08-24       Impact factor: 3.267

4.  Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study.

Authors:  Masoumeh Azimirad; Marcela Krutova; Abbas Yadegar; Shabnam Shahrokh; Meysam Olfatifar; Hamid Asadzadeh Aghdaei; Warren N Fawley; Mark H Wilcox; Mohammad Reza Zali
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

5.  Comparing the epidemiology of community- and hospital-associated Clostridium difficile infections in Northern Ireland, 2012-2016: a population data linkage and case-case study.

Authors:  A Maisa; G Ross; N Q Verlander; D Fairley; D T Bradley; L Patterson
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Transition From PCR-Ribotyping to Whole Genome Sequencing Based Typing of Clostridioides difficile.

Authors:  Helena M B Seth-Smith; Michael Biggel; Tim Roloff; Vladimira Hinic; Thomas Bodmer; Martin Risch; Carlo Casanova; Andreas Widmer; Rami Sommerstein; Jonas Marschall; Sarah Tschudin-Sutter; Adrian Egli
Journal:  Front Cell Infect Microbiol       Date:  2021-06-01       Impact factor: 5.293

7.  First genotypic characterization of toxigenic Clostridioides difficile in Lithuanian hospitals reveals the prevalence of the hypervirulent ribotype 027/ST1.

Authors:  Simona Tratulyte; Jolanta Miciuleviciene; Nomeda Kuisiene
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-20       Impact factor: 3.267

8.  The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.

Authors:  Dorota Wultańska; Michał Piotrowski; Hanna Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-03-05       Impact factor: 3.267

9.  The Colonisation of Calves in Czech Large-Scale Dairy Farms by Clonally-Related Clostridioides difficile of the Sequence Type 11 Represented by Ribotypes 033 and 126.

Authors:  Martina Masarikova; Ivana Simkova; Martin Plesko; Veronika Eretova; Marcela Krutova; Alois Cizek
Journal:  Microorganisms       Date:  2020-06-15

10.  Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region.

Authors:  Yun Luo; Elaine Cheong; Qiao Bian; Deirdre A Collins; Julian Ye; Jeong Hwan Shin; Wing Cheong Yam; Tohru Takata; Xiaojun Song; Xianjun Wang; Mini Kamboj; Thomas Gottlieb; Jianmin Jiang; Thomas V Riley; Yi-Wei Tang; Dazhi Jin
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.